What Is Thermage? Mechanism, Evidence of Efficacy, and Safety

Key summary. Thermage is a non-surgical lifting device that uses monopolar radiofrequency (RF) energy to protect the epidermis while heating the dermis and subcutaneous layers to stimulate collagen regeneration and skin tightening. In Korea, it is registered as a 3-grade medical device (general-purpose electrosurgical unit). It has become a standard comparison device, repeatedly adopted as an active control in recent clinical trials for new devices, and related systematic reviews report measurable improvement and generally favorable safety.

What this article covers

• Comparison criteria: energy type (monopolar RF) · target layer (dermis-focused) · level of efficacy evidence · safety
• Caution: monopolar devices are reported to have a higher rate of major complications compared with bipolar devices
• Evidence status: 1 reviews · 1 systematic reviews · 2 RCTs (including Thermage as an active control) · confirmed MFDS registration

Key points

1. Definition: a device that protects the epidermis with monopolar RF while broadly heating (bulk heating) the layers beneath to induce tightening.
2. Evidence of efficacy: in 2 comparison RCTs against new devices, Thermage (CPT model) was used as an active control and showed significant improvement.
3. Verification sequence: device registration status → practitioner qualifications → basis for efficacy claims → pain and safety information.

01How Does It Work

Thermage is described as cooling and protecting the epidermis with monopolar radiofrequency energy while relatively broadly heating (bulk heating) the dermis and subcutaneous tissue beneath it. This thermal stimulation is understood to stimulate collagen, producing a tightening effect. It is mainly reported for mild tightening of facial and periorbital wrinkles, lower-face wrinkles, and mild sagging. In Korea, Thermage FLX System (model TG-3A) is registered as a 3-grade medical device (general-purpose electrosurgical unit).

02What Research Has and Has Not Confirmed

The figures above are verified as of 2026-09-18 (PMID 41758257 was read in full text; the rest are based on abstracts). It should be noted that PMID 39957006 and PMID 41758257 are results in which Thermage was used as an "already validated comparison standard" within trials designed to verify new devices, and are not the latest independent large-scale studies of Thermage itself.

A non-inferiority trial is designed to test whether a new device is not worse than a comparison device beyond a predetermined margin. Therefore, a result showing no significant difference between the two groups cannot by itself be interpreted as meaning the two devices are entirely equivalent, or that Thermage has been newly and independently validated. In this article, that research is used not as evidence of Thermage's standalone superiority, but as limited data confirming the changes observed at 1, 3, and 6 months in the active control arm and whether serious adverse events were reported. Checking the full text of the multicenter study of 212 participants shows that the manufacturer of the new device (YOUMAGIC) directly supplied the research device (the authors reported no other conflicts of interest), that efficacy assessment relied mainly on a subjective scale (GAIS), and that the original text itself notes a limitation in generalizing by sex, since approximately 94% of participants were women (only 12 men).

03What to Check Before the Procedure

04Choosing by Condition

• Want mild tightening without incisions → consider radiofrequency options such as Thermage first
• Sensitive to pain → reported to be less painful than Ulthera based on direct-comparison RCTs, though individual differences exist
• Significant sagging → need to compare with surgical methods such as facelift

05Cautions and Conditions That May Vary

Systematic reviews report that the monopolar radiofrequency category has a higher rate of major complications (such as burns) than bipolar devices. However, individual RCTs (PMID 39957006, PMID 41758257) reported no serious adverse events, so it should also be considered that actual risk levels may vary depending on device settings and practitioner skill. This article is not medical advertising and does not guarantee results.

06Common misconceptions

"These RCTs are the latest independent validation of Thermage itself" — The two RCTs in table 2 (PMID 39957006, PMID 41758257) are trials that used Thermage as an "already validated comparison standard (active control)" to verify the efficacy of a new device. While Thermage did produce good results, the original texts also state that the primary purpose of these studies was to validate the new device, and that the manufacturer of that new device supplied the research device. These were not new, independent validation studies of Thermage itself.

"Monopolar radiofrequency is a dangerous procedure" — Systematic reviews reported that complications are mostly mild and transient, and the statement "monopolar is riskier than bipolar" refers to the relative rate of major complications such as burns, not to complications overall. In fact, in 2 individual recent RCTs, there were 0 serious adverse events.

"Since it's less painful than Ulthera, it must be the better procedure" — The direct-comparison RCT confirmed less pain, but found no statistical difference in efficacy, satisfaction, or side effects. Lower pain and better outcomes are separate conclusions in these studies.

07In summary

Thermage is a device that uses monopolar radiofrequency to broadly heat the dermal layer and produce a tightening effect, and it has accumulated enough evidence of efficacy to be used as a comparison standard for new devices in multiple RCTs. However, it is important to also recognize that the primary purpose of those RCTs was to validate new devices, and that the safety reports simultaneously contain both "generally mild" findings and the fact that "monopolar devices have a higher rate of major complications than bipolar devices." Rather than simple comparisons like "less painful" or "better," a more practical standard for judgment is checking during consultation whether the device is formally registered (수허 18-245 호) and how the practitioner prevents and manages risks such as burns.

08Frequently Asked Questions

Does Thermage actually work?

Significant improvement has been confirmed in multiple RCTs where it was used as an active control, including improvement in nasolabial fold depression and facial wrinkles (by GAIS score). However, since the primary purpose of these studies was to validate new devices, they are not the latest large-scale studies of Thermage alone.

Is Thermage safe?

A review of both monopolar and bipolar radiofrequency devices overall found that complications were mostly mild and transient, but there are reports that monopolar devices have a higher rate of major complications than bipolar devices. In 2 individual recent RCTs, there were no serious adverse events.

Which is better, Thermage or Ulthera?

In 2 direct-comparison RCTs, there was no statistical difference in efficacy, satisfaction, or side effects, and Ulthera caused more pain during the procedure. For a detailed comparison, see Ulthera vs. Thermage.

How can I verify that a Thermage device is genuine?

Formal registration in Korea can be verified through the MFDS medical device UDI lookup — Thermage FLX is registered as 수허 18-245 호. However, this lookup only shows whether the device itself has been approved; it does not confirm whether the clinic is actually using that device, so it is still necessary to ask the clinic directly about the specific device name during consultation.

09Pre-consultation checklist

• □ Checked the device name and MFDS registration status (수허 18-245 호)
• □ Confirmed the qualifications of the medical staff actually performing the procedure
• □ Confirmed that efficacy claims do not exceed the scope of the research (e.g., 6-month follow-up)
• □ Was informed about risks specific to monopolar radiofrequency, such as burns, and preventive measures
• □ Was informed about pain management methods (cooling, anesthesia)

10Sources and verification date

• PMID 18940540 — Verified as of 2026-09-18. A 2008 narrative review (not a systematic review, used only as a general overview source).
• PMID 35877937 — Verified as of 2026-09-18. A systematic review of monopolar and bipolar RF devices, 23 studies.
• PMID 39957006 — Verified as of 2026-09-18. RCT of new device vs. Thermage CPT, 40 participants.
• PMID 41758257 — Verified as of 2026-09-18. Multicenter RCT of new device vs. Thermage CPT, 212 participants. The original text explicitly notes limitations: the manufacturer of the new device supplied the research device, assessment relied mainly on a subjective scale, and 94% of participants were women.
• MFDS medical device UDI lookup — Thermage FLX 수허 18-245 호, verified as of 2026-09-17
• The research above is intended to explain the principle and efficacy of the procedure and does not guarantee outcomes for any specific clinic, practitioner, or patient.

11Editorial responsibility and interests

• Written by: Korea Beauty Report Editorial Team · Editorial responsibility: Korea Beauty Report Editorial Team
• Medical review: None — reviewed by the editorial team based on cited sources
• Conflicts of interest: No contracted or advertising relationship with any clinic mentioned in this article
• First published: 2026-09-18 · Sources last verified: 2026-09-18